Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 3 5Phase 1 2Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 16Active not recruiting 9Terminated 6Withdrawn 3Recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Biphenotypic, Acute 1

Interventions

Cyclophosphamide 118pembrolizumab 104Specimen Handling 104Magnetic Resonance Spectroscopy 94fludarabine 92Biopsy 77Injections 53Nivolumab 43Bevacizumab 41Fluorouracil 38venetoclax 37Cisplatin 36Paclitaxel 35Carboplatin 35Cetuximab 34Radiotherapy 31Oxaliplatin 30fludarabine phosphate 29Leucovorin 28Gemcitabine 28Drug Therapy 25Ipilimumab 23Immunotherapy, Adoptive 23Azacitidine 23Radiation 21Irinotecan 21Temozolomide 20Doxorubicin 20tislelizumab 19atezolizumab 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Recruiting × dexamethasone 21-phosphate × Clear all
NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Dana-Farber Cancer Institute

Phase 1 Recruiting
30 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06042725 2025-12-24

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Mayo Clinic

Phase 1 Recruiting
100 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡